The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis.
K. E. Bickel
No relevant relationships to disclose
J. C. Niland
No relevant relationships to disclose
R. Mamet
No relevant relationships to disclose
C. C. Zornosa
No relevant relationships to disclose
D. S. Ettinger
Employment or Leadership Position - NCCN; NCCN
K. Pisters
No relevant relationships to disclose
G. A. Otterson
Consultant or Advisory Role - Celgene; Genentech
Research Funding - Celgene; Genentech; Pfizer; Taj Pharmaceuticals
M. Koczywas
Consultant or Advisory Role - Genentech
Honoraria - Genentech; Lilly
Research Funding - GlycaNova
M. E. Reid
No relevant relationships to disclose
M. S. Rabin
No relevant relationships to disclose
T. A. D'Amico
Employment or Leadership Position - NCCN
C. Earle
No relevant relationships to disclose
T. M. Pini
No relevant relationships to disclose
G. P. Kalemkerian
Research Funding - Lilly; Pfizer